FLT3 and acute myeloid leukemia: It was further confirmed that, under the conditions where LJH685 alone did not show any significant effect, it significantly reduced viable cell numbers of primary FLT3-ITD-positive AML cells in combination with AZD1208 or GDC-0941 (Figure 6E).